Treatment of Skin Diseases by Delivery of an Anti-OSMR-Beta Antibody Blocking an Itch-and-Inflammation Signal

This patent describes treating skin diseases and disorders by giving an antibody that blocks a receptor called OSMR-beta, which sits at the heart of an itch-and-inflammation pathway. It comes from Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company focused on immune-driven diseases.

The Problem

Many chronic skin conditions combine relentless itch with inflammation, and the two feed each other: scratching damages the skin, which drives more inflammation and more itch. A signalling protein called oncostatin M and the related cytokine IL-31 act through a shared receptor component, OSMR-beta, to help drive both the itch sensation and the inflammatory response in the skin. Conventional treatments such as steroids can dampen inflammation broadly but often do not control the itch well and carry side effects with long-term use. There is a need for therapies that target the specific signal driving these symptoms rather than suppressing the immune system across the board.

What This Invention Does

The patent covers methods of treating skin diseases or disorders by delivering an antibody directed against OSMR-beta, the receptor subunit shared by the oncostatin M and IL-31 signalling pathways. By binding OSMR-beta, the antibody blocks signalling through that receptor, interrupting the pathway that drives itch and skin inflammation. The filing describes using such an anti-OSMR-beta antibody to treat conditions in which this pathway is active, setting out how the antibody is administered to patients to relieve symptoms. The IPC classifications point to antibody subject matter combined with treatment of skin conditions. Because the target sits at a shared point in two related signalling routes, blocking it aims to address both the itch and the inflammation with a single, targeted biologic rather than a broad immune suppressant.

Key Features

• Targeted antibody. The treatment uses an antibody that binds the OSMR-beta receptor subunit.
• Pathway blockade. Binding OSMR-beta blocks signalling shared by the oncostatin M and IL-31 routes.
• Itch and inflammation. The target sits at a point that drives both itch and skin inflammation.
• Defined use. The filing describes administering the antibody to treat skin diseases and disorders.
• Focused mechanism. The approach targets a specific signal rather than suppressing immunity broadly.

Who Is Behind It

The applicant is Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company that develops therapies for diseases with significant unmet need in immunology and inflammation. The named inventors are John Paolini, Rohan Gandhi, and Zamaneh Mikhak. This filing is a divisional application from an earlier related Australian application.

Why It Matters

Chronic itch is one of the most distressing and hard-to-treat symptoms in dermatology, and conditions that combine it with inflammation can severely affect quality of life. A biologic aimed precisely at the shared receptor driving both symptoms offers the promise of relief without the drawbacks of broad immune suppression. Protecting the treatment method in Australia supports the company’s development of the therapy for patients in the region.

Related Concepts

• Antibody – the type of targeted biologic used in this treatment.
• Oncostatin M – a cytokine that signals through the OSMR-beta receptor.
• Itch – the sensation the targeted pathway helps drive.
• Inflammation – the immune response the therapy aims to reduce.
• Monoclonal antibody therapy – the broader class of targeted antibody treatments.

---

AU 2026201985 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.